AAN 2014: Biogen Idec releases new trial data for peginterferon in MS

US biotech firm Biogen Idec (Nasdaq: BIIB) has released new two-year data from the Phase III ADVANCE clinical trial for peginterferon beta-1a in adults with relapsing forms of multiple sclerosis (RMS) at the 66th American Academy of Neurology (AAN) annual meeting.

The data shows that peginterferon beta-1a dosed once every two weeks demonstrated favourable results on relapse rates, magnetic resonance imaging (MRI) findings and disease progression. Over two years, the safety profile of peginterferon beta-1a was consistent with other multiple sclerosis (MS) interferon therapies.

Terry O’Regan, vice president and managing director at Biogen Idec, said: “The two-year data from ADVANCE further establish the efficacy and safety profile of peginterferon beta-1a demonstrated in the first year of the pivotal trial. If approved, we believe that peginterferon beta-1a dosed once every two weeks will provide MS patients with one of the most significant developments in the interferon class in over a decade.”